Cargando…

Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates

Mostrar otras versiones (1)

Many different vaccine candidates against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Doremalen, Neeltje, Fischer, Robert J., Schulz, Jonathan E., Holbrook, Myndi G., Smith, Brian J., Lovaglio, Jamie, Petsch, Benjamin, Munster, Vincent J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282095/ https://www.ncbi.nlm.nih.gov/pubmed/34268507 http://dx.doi.org/10.1101/2021.07.07.451505

Ejemplares similares

Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Updated and Validated Pan-Coronavirus PCR Assay to Detect All Coronavirus Genera
por: Holbrook, Myndi G., et al.
Publicado: (2021)

Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2
por: Port, Julia, et al.
Publicado: (2021)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?
por: Pettini, Elena, et al.
Publicado: (2021)

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models
por: Roth, Nicole, et al.
Publicado: (2023)

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
por: Fournillier, Anne, et al.
Publicado: (2013)

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
por: Tukhvatulin, Amir I., et al.
Publicado: (2022)

Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2
por: Port, Julia R., et al.
Publicado: (2021)

SARS-CoV-2 vaccines: anamnestic response in previously infected recipients
por: Purushotham, Jyothi N., et al.
Publicado: (2021)

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant
por: Yinda, Claude Kwe, et al.
Publicado: (2021)

Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model
por: Kalnin, Kirill V., et al.
Publicado: (2022)

SARS-CoV-2 disease severity and transmission efficiency is increased for airborne but not fomite exposure in Syrian hamsters.
por: Port, Julia R., et al.
Publicado: (2020)

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
por: Tan, Hyon-Xhi, et al.
Publicado: (2021)

Analysis of R848 as an Adjuvant to Improve Inactivated Influenza Vaccine Immunogenicity in Elderly Nonhuman Primates
por: Crofts, Kali F., et al.
Publicado: (2022)

ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters
por: Port, Julia R., et al.
Publicado: (2022)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Modeling the effect of boost timing in murine irradiated sporozoite prime-boost vaccines
por: Fernandez-Arias, Cristina, et al.
Publicado: (2018)

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters
por: Port, Julia R., et al.
Publicado: (2023)

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
por: Venkatraman, Navin, et al.
Publicado: (2019)

SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters
por: Port, Julia R., et al.
Publicado: (2021)

Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens
por: Tan, Wendy G., et al.
Publicado: (2017)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
por: Cheng, Haoyue, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
por: Sablerolles, Roos S.G., et al.
Publicado: (2022)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin
por: Mould, Robert C., et al.
Publicado: (2021)

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates
por: Rollier, C S, et al.
Publicado: (2016)

Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer
por: Sersa, Gregor, et al.
Publicado: (2015)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Can existing unrelated vaccines boost a COVID-19 vaccine prime?
por: Hupert, Nathaniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7572qlmq3fgkhvfjjt45q378kt